Centogene N.V. Share Price

Equities

CNTG

NL0014040206

Biotechnology & Medical Research

Market Closed - Nasdaq 21:30:00 26/04/2024 BST 5-day change 1st Jan Change
0.4889 USD +1.88% Intraday chart for Centogene N.V. +7.24% -59.26%

Financials

Sales 2023 * 48.62M 51.99M 4.16B Sales 2024 * 59.5M 63.62M 5.09B Capitalization 12.76M 13.64M 1.09B
Net income 2023 * -48M -51.32M -4.11B Net income 2024 * -45M -48.11M -3.85B EV / Sales 2023 * 0.26 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 0.21 x
P/E ratio 2023 *
-0.29 x
P/E ratio 2024 *
-0.47 x
Employees 444
Yield 2023 *
-
Yield 2024 *
-
Free-Float 69.49%
More Fundamentals * Assessed data
Dynamic Chart
Centogene Gets Nasdaq Noncompliance Notice MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics MT
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders CI
Centogene Explores Strategic Alternatives CI
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration CI
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics CI
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 CI
Centogene N.V. Announces Changes to Supervisory Board CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone CI
Centogene, Saudi Arabia's Public Investment Fund Form JV MT
Centogene N.V. and Lifera Complete Strategic Joint Venture Transaction CI
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism CI
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering CI
Flemming Ornskov Decides to Step Down from His Role as a Member of the Supervisory Board of Centogene CI
Centogene N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+1.88%
1 week+7.24%
Current month-31.14%
1 month-29.14%
3 months-57.11%
6 months-53.60%
Current year-59.26%
More quotes
1 week
0.44
Extreme 0.4408
0.55
1 month
0.43
Extreme 0.431
0.75
Current year
0.43
Extreme 0.431
1.25
1 year
0.43
Extreme 0.431
1.98
3 years
0.43
Extreme 0.431
11.95
5 years
0.43
Extreme 0.431
28.71
10 years
0.43
Extreme 0.431
28.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 19/12/21
Director of Finance/CFO - 07/02/22
Chief Tech/Sci/R&D Officer 64 15/08/21
Members of the board TitleAgeSince
Chairman 57 15/03/20
Director/Board Member 57 30/06/17
Director/Board Member 66 31/03/19
More insiders
Date Price Change Volume
26/04/24 0.4889 +1.88% 6,941
25/04/24 0.4799 +4.10% 7,168
24/04/24 0.461 -3.96% 19,900
23/04/24 0.48 +2.11% 71,989
22/04/24 0.4701 +3.11% 434,353

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.458 EUR
Average target price
1.378 EUR
Spread / Average Target
+200.90%
Consensus